HomeSlots › Bizarre
Nolimit City

Bizarre Slot Review

★★★★★ 4.6 / 5 — our rating
ESReviewed by Elin Sundqvist, Casino Analyst · Updated 14 Aug 2026
RTP
96.06%
Volatility
Very High
Max Win
20,000×
Provider
Nolimit City

Symbols split in two wherever xSplit lands, multiplying ways to win on the road to a 20,000x-stake ceiling. Nolimit City released Bizarre on November 18, 2025, built on its trademarked xSplit® engine. Bonus play comes in two tiers: Chimera Spins and Super Chimera Spins. RTP is 96.06%, with high volatility throughout.

How Bizarre plays

Bizarre is built for extreme variance. Long cold runs are punctuated by rare, outsized wins; this one swings hard both ways and isn't for the faint-hearted. The headline number backs it up: a top prize of 20,000× your stake.

Is 96.06% a good RTP?

96.06% puts Bizarre right on the industry standard of around 96% — a fair, typical return with no nasty surprises in the maths. Bear in mind RTP is a long-run theoretical figure, not a promise for any single session.

Who should play it

Bizarre is aimed at players who chase the big multiplier and can stomach the dry spells to get there. If losing streaks tilt you, a lower-variance title on this list will feel better.

What we liked

  • Solid 96.06% RTP, at or above standard
  • Rare but potentially huge hits (very high volatility)
  • Max win of 20,000× the stake
  • From Nolimit City, a studio we rate

Worth knowing

  • Very high-volatility play: long dry spells are part of the deal
  • Bonus features can be slow to trigger

Want to try Bizarre in demo or real-money mode?

Play at Casumo →

Frequently asked questions

What is the RTP of Bizarre?
Bizarre has a published return-to-player (RTP) of 96.06%.
What is the volatility of Bizarre?
Bizarre is a very high-volatility slot, meaning rare but potentially huge hits.
What is the maximum win on Bizarre?
The maximum win on Bizarre is 20,000× your stake.
Who makes Bizarre?
Bizarre is developed by Nolimit City.

How we review: we verify each game's RTP, volatility and maximum win against provider data, then assess variance, features and value. Ratings reflect our editorial judgement, not commercial arrangements. Read our full methodology →